Iterative Chemical Engineering of Vancomycin Leads to Novel Vancomycin Analogs With a High in Vitro Therapeutic Index

Vancomycin is a glycopeptide antibiotic that inhibits transpeptidation during cell wall synthesis by binding to the D-Ala-D-Ala termini of lipid II. For long, it has been used as a last resort antibiotic. However, since the emergence of the first vancomycin-resistant enterococci in 1987, vancomycin resistance has become widespread, especially in hospitals. We have synthesized and evaluated 110 vancomycin analogs modified at the C-terminal carboxyl group of the heptapeptide moiety with R2NHR1NH2 substituents. Through iterative optimizations of the substituents, we identified vancomycin analogs that fully restore (or even exceed) the original inhibitory activity against vancomycin-resistant enterococci (VRE), vancomycin-intermediate (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) strains. The best analogs have improved growth inhibitory activity and in vitro therapeutic indices against a broad set of VRE and methicillin-resistant S. aureus (MRSA) isolates. They also exceed the activity of vancomycin against Clostridium difficile ribotypes. Vanc-39 and Vanc-42 have a low probability to provoke antibiotic resistance, and overcome different vancomycin resistance mechanisms (VanA, VanB, and VanC1).

[1]  Peng Tao,et al.  Insights into Key Interactions between Vancomycin and Bacterial Cell Wall Structures , 2018, ACS omega.

[2]  Feifei Chen,et al.  Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. , 2018, Journal of medicinal chemistry.

[3]  D. Schols,et al.  Design, Synthesis, and the Biological Evaluation of a New Series of Acyclic 1,2,3‐Triazole Nucleosides , 2017, Archiv der Pharmazie.

[4]  D. Boger,et al.  Peripheral modifications of [Ψ[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics , 2017, Proceedings of the National Academy of Sciences.

[5]  D. Boger,et al.  Total Syntheses of Vancomycin-Related Glycopeptide Antibiotics and Key Analogues. , 2017, Chemical reviews.

[6]  J. Vanderleyden,et al.  Evaluation of the antibacterial and antibiofilm activities of novel CRAMP-vancomycin conjugates with diverse linkers. , 2015, Organic & biomolecular chemistry.

[7]  J. Haldar,et al.  Membrane active vancomycin analogues: a strategy to combat bacterial resistance. , 2014, Journal of medicinal chemistry.

[8]  D. Boger,et al.  Probing the role of the vancomycin e-ring aryl chloride: selective divergent synthesis and evaluation of alternatively substituted E-ring analogues. , 2013, Journal of medicinal chemistry.

[9]  M. Preobrazhenskaya,et al.  Synthesis and study of antibacterial activities of antibacterial glycopeptide antibiotics conjugated with benzoxaboroles. , 2013, Future medicinal chemistry.

[10]  M. Gilmore,et al.  Genetic Basis for Daptomycin Resistance in Enterococci , 2011, Antimicrobial Agents and Chemotherapy.

[11]  A. Bonvin,et al.  The vancomycin-nisin(1-12) hybrid restores activity against vancomycin resistant Enterococci. , 2008, Biochemistry.

[12]  C. Surawicz,et al.  Current Treatment Options for Severe Clostridium difficile-associated Disease. , 2008, Gastroenterology & hepatology.

[13]  D. Boger,et al.  Total synthesis and evaluation of [Psi[CH2NH]Tpg4]vancomycin aglycon: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding. , 2006, Journal of the American Chemical Society.

[14]  M. Preobrazhenskaya,et al.  Structure-activity relationships in a series of semisynthetic polycyclic glycopeptide antibiotics , 2006, Russian journal of bioorganic chemistry.

[15]  J. Shaw,et al.  Vancomycin disulfide derivatives as antibacterial agents. , 2004, Bioorganic & medicinal chemistry letters.

[16]  S. Walker,et al.  Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  F. Tenover,et al.  Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus , 2003, Journal of Clinical Microbiology.

[18]  P. Courvalin,et al.  vanE Gene Cluster of Vancomycin-Resistant Enterococcus faecalis BM4405 , 2002, Journal of bacteriology.

[19]  J. Turnidge,et al.  Genetic Characterization of vanG, a Novel Vancomycin Resistance Locus of Enterococcus faecalis , 2000, Antimicrobial Agents and Chemotherapy.

[20]  C. Walsh.  Deconstructing Vancomycin , 1999, Science.

[21]  K. Burgess,et al.  Total Syntheses of Vancomycin. , 1999, Angewandte Chemie.

[22]  F. Tenover,et al.  Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides , 1998, Journal of Clinical Microbiology.

[23]  T. Nicas,et al.  Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic , 1996, Antimicrobial agents and chemotherapy.

[24]  C. Walsh,et al.  Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. , 1996, Chemistry & biology.

[25]  H. A. Snaith,et al.  Analysis of peptidoglycan precursors in vancomycin-resistant Enterococcus gallinarum BM4174. , 1994, The Biochemical journal.

[26]  M. Arthur,et al.  Genetics and mechanisms of glycopeptide resistance in enterococci , 1993, Antimicrobial Agents and Chemotherapy.

[27]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[28]  J. Santoro,et al.  Vancomycin. A new old agent. , 1989, Infectious disease clinics of North America.

[29]  C. Harris,et al.  VANCOMYCIN: STRUCTURE AND TRANSFORMATION TO CDP-I , 1983 .

[30]  D. Hoover,et al.  Characterization of staphylococci , 1983, Applied and environmental microbiology.

[31]  J. Nikokavouras.  Synthesis and study of , 1971 .

[32]  D. Boger,et al.  Vancomycin Aglycon : Reengineering Vancomycin for Dual DAla-DAla and DAla-D-Lac Binding , 2022 .